This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John W. Hadden, MD; James Endicott, MD; Paul Baekey, MD; Paulette Skipper; Elba M. Hadden, PhD

Arch Otolaryngol Head Neck Surg. 1994;120(4):395-403.

Abstract
Metastatic squamous cell head and neck cancer was treated in four patients with low-dose cyclophosphamide (to reduce suppressor T-cell activity), indomethacin (to reduce prostaglandins that mediate macrophage-induced immune suppression), zinc (to augment T-cell function via thymulin), and mixed natural interleukins perilymphatically in the neck (as adjuvant for tumor antigen in the region). Three patients responded within 7 days with major tumor regressions progressive during the period of treatment and associated with increased infiltration with lymphocytes and tumor cell lysis. Two showed histologic features of intense delayed hypersensitivity with granulomatous changes. The fourth patient was anergic and failed to respond clinically. Tumor-specific immune response, despite preexisting immunodeficiency, is postulated as the mechanism of the responses in these patients.

(Arch Otolaryngol Head Neck Surg. 1994;120:395-403)

Author Affiliations
From the Departments of Internal Medicine (Drs Hadden and Hadden), Pathology (Dr Backey), and Surgery (Dr Endicott and Ms Skipper), University of South Florida Medical College, Tampa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial
Timar et al.
JCO 2005;23:3421-3432.
ABSTRACT | FULL TEXT  

Report of a Clinical Trial in 12 Patients With Head and Neck Cancer Treated Intratumorally and Peritumorally With Multikine
Feinmesser et al.
Arch Otolaryngol Head Neck Surg 2003;129:874-881.
ABSTRACT | FULL TEXT  

Combination Immunotherapy of Squamous Cell Carcinoma of the Head and Neck: A Phase 2 Trial
Barrera et al.
Arch Otolaryngol Head Neck Surg 2000;126:345-351.
ABSTRACT | FULL TEXT